Brought to you by www.DealSearchOnline.com
March 11, 2013 Issue:
Recent Health Care M&A Deals
BIOTECHNOLOGY
BioReliance
Rights to Big Blue Colonies and Cell Lines
N/A
E-HEALTH
Acquirer
Target
Price
Allscripts
dbMotion, Ltd.
$235 million
NetDimensions
eHealthcareIT
$3.5 million
Acquirer
Target
Price
Health Management Corporation of America
Health Diagnostics Management, LLC
$34.4 million
MEDICAL DEVICES
Acquirer
Target
Price
TranS1 Inc.
Baxano, Inc.
$23.6 million
HCC Best Practices for Proactive Medical Management
March 18-19, 2013 – Sheraton Music City Hotel – Nashville, TN
We are pleased to announce our 4th Annual HCC Best Practices conference. This conference will build on the success of the 2011 and 2012 conferences while providing practical, timely updates to help you continue to evolve your medical management practices with sound HCC coding.
www.opalevents.org/trk/hccb1301.html
Service Deal of the Week
HCMA, a subsidiary of Fonar Corporation (NASDAQ: FONR), announced it had paid $34.4 million for a majority interest in a new company, Health Diagnostics Management, LLC, a national provider of outpatient diagnostic imaging services, including 12 Stand-Up® MRI centers, in New York and Florida. HCMA manages 11 Stand-Up® centers, so the combined company now forms the largest U.S. network of Stand-Up® MRI imaging centers with a total of 23. Fonar, it should be noted, is The Inventor of MR Scanning™, so the deal is naturally expected to bring economies of scale, joint marketing strategies and benefits from sharing administrative and technical expertise……..Want to read more news? Click here for a free trial to The Health Care M&A Information Source and download the current issue today.
Charted Territory
The Pharmaceuticals category woke up in February, as strategic deals were made for some pharma companies and the rights to several successful drugs changed hands. The biggest deal was for $3.25 billion for Tysabri, which Biogen Idec (NASDAQ: BIIB) developed in partnership with Elan Corporation (NYSE: ELN). The $1.6 billion all-cash bid made by Mylan, Inc. (NASDAQ: MYL) for Agila Specialties Private Limited provides for an additional $250 million in potential payments, subject to the satisfaction of certain conditions made by Agila’s owner, Strides Arcolab Limited (NSE: STAR). Rosemont Pharmaceuticals, which makes specialty and generic prescription drugs, found a new home with Perrigo Company (NASDAQ: PRGO), its third owner in 11 years.
Top Pharmaceuticals Deals, February 2013
Target
Acquirer
Price
Rights to Tysabri
Biogen Idec, Inc.
$3,250,000,000
Agila Specialties Private Limited
Mylan, Inc.
$1,600,000,000
Rosemont Pharmaceuticals Ltd.
Perrigo Company
$283,000,000
Rights to ALN-PCS
The Medicines Company
$25,000,000
Aurinia Pharmaceuticals
Isotechnika Pharma Inc.
$3,860,000
Rights to Voclosporin
Aurinia Pharmaceuticals
$1,450,000
Want to read more news? Click here for a free trial to The Health Care M&A Information Source and download the current issue today
Technology Deal of the Week
Allscripts (NASDAQ: MDRX) was on the acquisition trail last week as it announced a $235 million bid for privately held dbMotion, Ltd. and an undisclosed amount for Jardogs LLC. The dbMotion acquisition is a natural evolution of a strategic partnership that began in 2009 and strengthened in 2011 when Allscripts made an equity investment in the company. This deal consists of $145 million in cash, $50 million of Allscripts common stock and $40 in cash via a note payable, due within 18 months. dbMotion provides clinicians with point-of-care patient information in 370 hospitals and 2,800 clinics around the world. The Jardogs FollowMyHealth patient engagement platform lets patients actively participate in their health care, particularly at-risk populations. Allscripts expects the transactions to be slightly dilutive in 2013 and accretive in 2014……Want to read more news? Click here for a free trial to The Health Care M&A Information Source and download the current issue today.
In the Pipeline
Medical device company Nevro Corp., which focuses on improving pain relief in patients suffering from debilitating chronic pain, announced on March 7 that it had completed a $48 million Series C financing round. The funds are earmarked for Nevro’s ongoing pivotal clinical study in the U.S., to invest in clinical evidence for new indications and to support the company’s domestic and international commercialization plans. Its Senza® high-frequency spinal cord stimulation system is authorized for sale and available at leading centers in Europe and Australia. In the U.S., the system is limited by federal law to investigational use and is not yet available for promotion or sale. But $48 million should help to alleviate that situation…..Want to read more news? Click here for a free trial to The Health Care M&A Information Source and download the current issue today.
NEW – The Health Care Services Acquisition Report, 19th Edition – Preorder Today!
Deals have been made. The 2013 Health Care Services Acquisition Report contains private deals in this market that are too small to make it into the financial press. Take advantage of our limited 2-for-1 offer – preorder The 2013 Health Care Services Acquisition Report by March 31st and receive The 2012 Health Care Services Acquisition Report FREE ($595 value)! Now that’s a recession resistant deal. Go to http://www.levinassociates.com/hardescription or call 800-248-1668 to preorder today!
Conference Calendar…Click here to see more
